ArticleBiomaterials2013
The blood and vascular cell compatibility of heparin-modified ePTFE vascular grafts.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 266 citations in OpenAlex.
- Copolymers of Poly(Butylene Trans-1,4-Cyclohexanedicarboxylate)/Pripol as New Biomaterial Platform for Small Diameter Vascular Graft.Advanced healthcare materials · 2026Article
- Ascorbate elastomer-coated ePTFE grafts inhibit neointimal hyperplasia and enhance vascular healing.Bioactive materials · 2026Article
- Advances in Surface Biofunctionalization and Intelligent Monitoring of Vascular Scaffolds.Research (Washington, D.C.) · 2026Review
- Using Low-Speed Rotation in Heparin Immobilization Improved Antithrombogenicity of Tubular Acellular Vascular Scaffolds.Tissue engineering and regenerative medicine · 2026Article
- Bioinert Fibrous Polypropylene Membranes via In Situ Polymerization of Zwitterionic Poly(sulfobetaine methacrylate).Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Nonadhesive membranes: preparation and characterization of modified PHBHX membranes.Turkish journal of chemistry · 2025Article
- Improving the hemocompatibility of a porohyperelastic layered vascular graft using luminal reversal microflows.Journal of the mechanical behavior of biomedical materials · 2024Article
- Citric Acid: A Nexus Between Cellular Mechanisms and Biomaterial Innovations.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Review
- Design and Synthesis of P(AAm-co-NaAMPS)-Alginate-Xanthan Hydrogels and the Study of Their Mechanical and Rheological Properties in Artificial Vascular Graft Applications.Gels (Basel, Switzerland) · 2024Article
- Biomedical applications of engineered heparin-based materials.Bioactive materials · 2024Review
- Anti-thrombotic poly(AAm-co-NaAMPS)-xanthan hydrogel-expanded polytetrafluoroethylene (ePTFE) vascular grafts with enhanced endothelialization and hemocompatibility properties.Biomaterials advances · 2023Article
- Endothelium-Mimetic Surface Modification Improves Antithrombogenicity and Enhances Patency of Vascular Grafts in Rats and Pigs.JACC. Basic to translational science · 2023Article
- Covalent coating strategy for enhancing the biocompatibility and hemocompatibility of blood-contacting medical materials.Pharmaceutical science advances · 2023Review
- Directed self-assembly of a xenogeneic vascularized endocrine pancreas for type 1 diabetes.Nature communications · 2023Article
- Optimizing the Porohyperelastic Response of a Layered Compliance Matched Vascular Graft to Promote Luminal Self-Cleaning.Journal of biomechanical engineering · 2023Article
- Engineering multifunctional bioactive citrate-based biomaterials for tissue engineering.Bioactive materials · 2023Review
- Article
- Challenge of material haemocompatibility for microfluidic blood-contacting applications.Frontiers in bioengineering and biotechnology · 2023Review
- Surface Coating of Polyurethane Films with Gelatin, Aspirin and Heparin to Increase the Hemocompatibility of Artificial Vascular Grafts.Advanced pharmaceutical bulletin · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Prosthetic vascular grafts do not mimic the antithrombogenic properties of native blood vessels and therefore have higher rates of complications that involve thrombosis and restenosis. We developed an approach for grafting bioactive heparin, a potent anticoagulant glycosaminoglycan, to the lumen of ePTFE vascular grafts to improve their interactions with blood and vascular cells. Heparin was bound to aminated poly(1,8-octanediol-co-citrate) (POC) via its carboxyl functional groups onto POC-modified ePTFE grafts. The bioactivity and stability of the POC-immobilized heparin (POC-Heparin) were characterized via platelet adhesion and clotting assays. The effects of POC-Heparin on the adhesion, viability and phenotype of primary endothelial cells (EC), blood outgrowth endothelial cells (BOECs) obtained from endothelial progenitor cells (EPCs) isolated from human peripheral blood, and smooth muscle cells were also investigated. POC-Heparin grafts maintained bioactivity under physiologically relevant conditions in vitro for at least one month. Specifically, POC-Heparin-coated ePTFE grafts significantly reduced platelet adhesion and inhibited whole blood clotting kinetics. POC-Heparin supported EC and BOEC adhesion, viability, proliferation, NO production, and expression of endothelial cell-specific markers von Willebrand factor (vWF) and vascular endothelial-cadherin (VE-cadherin). Smooth muscle cells cultured on POC-Heparin showed increased expression of α-actin and decreased cell proliferation. This approach can be easily adapted to modify other blood contacting devices such as stents where antithrombogenicity and improved endothelialization are desirable properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.